Long-term add-on pregabalin treatment in patients with partial-onset epilepsy: Pooled analysis of open-label clinical trials

Epilepsia

Volumn 51, Issue 6, 2010, Pages 968-978

  Uthman, Basim M ^a   Bazil, Carl W ^b   Beydoun, Ahmad ^c   Schulze Bonhage, Andreas ^d   Benabou, Reina ^e   Whalen, Ed ^e   Emir, Birol ^e   Griesing, Teresa ^e   Leon, Teresa ^e  

^a WEILL CORNELL MEDICAL COLLEGE   (Qatar)

^b Columbia University ^*  (United States)

^c AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^d UNIVERSITY OF FREIBURG   (Germany)

^e Pfizer Global Pharmaceuticals   (United States)

Author keywords

Antiepileptic drugs; Clinical trials; Epilepsy; Long term therapy; Open label; Pregabalin

Indexed keywords

PREGABALIN;

ACCIDENTAL INJURY; ADD ON THERAPY; AMBLYOPIA; ARTICLE; ASTHENIA; ATAXIA; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DIPLOPIA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPILEPTIC STATE; FOCAL EPILEPSY; HEADACHE; HUMAN; INFECTION; LONG TERM CARE; MALIGNANT NEOPLASTIC DISEASE; MORTALITY; PAIN; PRIORITY JOURNAL; SIDE EFFECT; SOMNOLENCE; SUDDEN DEATH; TREATMENT DURATION; WEIGHT GAIN;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CLINICAL TRIALS AS TOPIC; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EPILEPSIES, PARTIAL; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77954632713     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2010.02532.x     Document Type: Article

References (29)

1. Abou-Khalil BW, Vazquez BR, Beydoun AA, Elger CE, Biton V, Krauss GL, Smith TM, Greiner MJ, Knapp LE, Bockbrader HN, Garofalo EA, the Pregabalin 7/8 Study Group. (1999) Pregabalin in-patient monotherapy trial: study results and impact of seizure frequency on efficacy evaluations. Epilepsia 40(suppl 7):109.
2. Arroyo S, Anhut H, Kugler AR, Lee CM, Knapp LE, Garofalo EA, Messmer S, the Pregabalin 1008-011 International Study Group. (2004) Pregabalin add-on treatment: a randomized double-blind placebo-controlled dose-response study in adults with partial seizures. Epilepsia 45:20-27.
3. Baker GA. (2002) The psychosocial burden of epilepsy. Epilepsia 43(suppl 6):26-30.
4. Baker GA, Jacoby A, Buck D, Stalgis C, Monnet D. (1997) Quality of life of people with epilepsy: a European study. Epilepsia 38:353-362. (Pubitemid 27147650)
5. Ben-Menachem E. (2004) Pregabalin pharmacology and its relevance to clinical practice. Epilepsia 45(suppl 6):13-18.
6. Beydoun A, Uthman BM, Kugler AR, Greiner MJ, Knapp LE, Garofalo EA, the Pregabalin 1008-009 Study Group. (2005) Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy. Neurology 64:475-480.
7. Bockbrader HN, Burger PJ, Kugler AR, Knapp LE, Garofalo EA, Lalonde RL. (2001) Population pharmacokinetic (PK) analyses of commonly prescribed antiepileptic drugs (AEDs) coadministered with pregabalin (PGB) in adult patients with refractory partial seizures. Epilepsia 42(suppl 7):84.
8. Brodie MJ. (2004) Pregabalin as adjunctive therapy for partial seizures. Epilepsia 45(suppl 6):19-27.
9. Brodie MJ, Kwan MD. (2002) Staged approach to epilepsy management. Neurology 58:S2-S8.
10. Brodie MJ, Wilson EA, Wesche DL, Alvey CW, Randinitis EJ, Posvar EL, Hounslow NJ, Bron NJ, Gibson GL, Bockbrader HN. (2005) Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy. Epilepsia 46:1407-1413.
11. Commission on Classification and Terminology of the International League against Epilepsy. (1981) Proposal for revised clinical and electroencephalographic classification of epileptic seizures: from the Commission on Classification and Terminology of the International League against Epilepsy. Epilepsia 22:489-501.
12. Datta PK, Crawford PM. (2000) Refractory epilepsy: treatment with new antiepileptic drugs. Seizure 9:51-57. (Pubitemid 30099237)
13. Department of Health and Human Services. (1996) Coding symbols for a thesaurus of adverse event reaction terms (COSTART), 4th ed. Department of Health and Human Services, US Food and Drug Administration (FDA), Rockville, MD.
14. Dooley DJ, Donovan CM, Meder WP, Whetzel S. (2002) Preferential action of gabapentin and pregabalin at P/Q-type voltage-sensitive calcium channels: inhibition of K+-evoked [3H]-norepinephrine release from rat neocortical slices. Synapse 45:171-190.
15. Elger CE, Brodie MJ, Anhut H, Lee CM, Barrett JA. (2005) Pregabalin add-on treatment in patients with partial seizures: a novel evaluation of flexible-dose and fixed-dose treatment in a double-blind, placebo-controlled study. Epilepsia 46:926-1936.
16. Fink K, Dooley DJ, Meder WP, Suman-Chauhan N, Duffy S, Clusmann H, Gothert M. (2002) Inhibition of neuronal Ca2+ influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 42(2):229-236. (Pubitemid 34137026)
17. French JA, Kugler AR, Robbins JL, Knapp LE, Garofalo EA. (2003) Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology 60:1631-1637. (Pubitemid 36618090)
18. Koepp MJ, Edwards M, Collins J, Farrel F, Smith S. (2005) Status epilepticus and tiagabine therapy revisited. Epilepsia 46:1625-1632. (Pubitemid 44921937)
19. Landmark CJ, Rytter E, Johannessen SI. (2007) Clinical use of antiepileptic drugs at a referral centre for epilepsy. Seizure 16(4):356-64.
20. Miller R, Frame B, Corrigan B, Burger P, Bockbrader H, Garofalo E, Lalonde R. (2003) Exposure-response analysis of pregabalin add-on treatment of patients with refractory seizures. Clin Pharmacol Ther 73:491-505.
21. Nashef L, Fish DR, Garner S, Sander JW, Shorvon SD. (1995) Sudden death in epilepsy: a study of incidence in a young cohort with epilepsy and learning difficulty. Epilepsia 36:1187-1194.
22. National Cancer Institute, NIH, DHHS (2005) Cancer Trends Progress Report - 2005 Update. Published online: Dec 2005.
23. Ryvlin P. (2005) Defining success in clinical trials - profiling pregabalin, the newest AED. Eur J Neurol 12(suppl 4):12-21.
24. Shorvon SD. (1996) The epidemiology and treatment of chronic and refractory epilepsy. Epilepsia 37(suppl 2):S1-S3.
25. Taylor CP, Vartanian MG, Yuen P, Bigge C, Suman-Chauhan N, Hill DR. (1993) Potent and stereospecific anticonvulsant activity of 3-isobutyl GABA relates to in vitro binding at a novel site labelled by tritiated gabapentin. Epilepsy Res 14:11-15. (Pubitemid 23030521)
26. Tellez-Zenteno JF, Ronquillo LH, Weibe S. (2005) Sudden unexpected death in epilepsy: evidence-based analysis of incidence and risk factors. Epilepsy Res 65:101-115. (Pubitemid 41039048)
27. Tomson T, Walczak T, Sillanpaa M, Sander JW. (2005) Sudden unexpected death in epilepsy: a review of incidence and risk factors. Epilepsia 46(suppl 11):54-61.
28. Wong IC, Lhatoo SD. (2000) Adverse reactions to new anticonvulsant drugs. Drug Saf 23:35-56. (Pubitemid 30455916)
29. Zaccara G, Messori A, Cincotta M, Burchini G. (2006) Comparison of the efficacy and tolerability of new antiepileptic drugs: what can we learn from long-term studies? Acta Neurol Scand 114(3):157-68.